AstraZeneca/£AZN
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
£AZN
Sector
Primary listing
LSE
Employees
94,300
Headquarters
Website
AstraZeneca Metrics
BasicAdvanced
£195B
31.19
£4.02
0.15
£2.45
1.95%
Price and volume
Market cap
£195B
Beta
0.15
52-week high
£129.72
52-week low
£95.74
Average daily volume
2.2M
Dividend rate
£2.45
Financial strength
Current ratio
0.863
Quick ratio
0.664
Long term debt to equity
57.992
Total debt to equity
73.508
Dividend payout ratio (TTM)
59.51%
Interest coverage (TTM)
10.77%
Profitability
EBITDA (TTM)
14,476.262
Gross margin (TTM)
82.26%
Net profit margin (TTM)
14.68%
Operating margin (TTM)
25.40%
Effective tax rate (TTM)
17.17%
Revenue per employee (TTM)
£454,080
Management effectiveness
Return on assets (TTM)
8.28%
Return on equity (TTM)
19.67%
Valuation
Price to earnings (TTM)
31.189
Price to revenue (TTM)
4.543
Price to book
4.35
Price to tangible book (TTM)
-13.49
Price to free cash flow (TTM)
30.828
Free cash flow yield (TTM)
3.24%
Free cash flow per share (TTM)
4.064
Dividend yield (TTM)
1.95%
Growth
Revenue change (TTM)
15.00%
Earnings per share change (TTM)
28.86%
3-year revenue growth (CAGR)
8.66%
10-year revenue growth (CAGR)
8.20%
3-year earnings per share growth (CAGR)
86.70%
10-year earnings per share growth (CAGR)
18.97%
3-year dividend per share growth (CAGR)
2.58%
10-year dividend per share growth (CAGR)
1.12%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Bulls say / Bears say
Second-quarter 2025 revenue rose 11% year-on-year to $14.46 billion and core EPS reached $2.17, both surpassing analyst forecasts and underscoring robust top-line and profitability momentum (Reuters)
Oncology product sales climbed 18% to $6.31 billion, led by strong performances from Tagrisso, Lynparza, and Imfinzi, outperforming expectations and validating its oncology-centric strategy (Reuters)
Baxdrostat met the primary endpoint in a late-stage Phase III trial for treatment-resistant hypertension, paving the way for regulatory filings by year-end 2025 and targeting over $5 billion in peak annual sales (Reuters)
Faces potential import tax fine of up to $8 million in China over suspected unpaid Enhertu import taxes, risking penalties and disruptions in a market representing about 12% of sales (Reuters)
Despite beating Q2 expectations, AstraZeneca maintained its full-year outlook due to ongoing pricing pressures and global trade uncertainties, signaling potential headwinds to revenue growth (Reuters)
Delay of late-stage AVANZAR lung cancer trial data to the first half of 2026 postpones anticipated oncology revenue contributions, introducing timing risk for its pipeline-driven growth (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of £195B as of October 30, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 31.19 as of October 30, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of October 30, 2025, the dividend rate is £2.447 and the yield is 1.95%. AstraZeneca has a payout ratio of 59.51% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.